← Back to Search

Protein Concentrate

APIC-CF 4cc, for Osteoarthritis

Phase 1 & 2
Waitlist Available
Research Sponsored by Cytonics Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 week

Summary

This trial uses a device to concentrate a substance from a patient's blood and inject it into their painful knee. The substance helps stop harmful elements from breaking down knee tissue, aiming to reduce pain and slow joint damage. A new blood-based treatment has been developed to concentrate helpful components and reduce inflammation, with promising early results in terms of safety and improvement.

Eligible Conditions
  • Osteoarthritis
  • Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reduction in pain after 8 weeks
Reduction in pain while walking at 8 weeks
Secondary study objectives
Reduction in pain after 2 weeks
Reduction in pain at 24 weeks
Reduction in pain while walking after 24 weeks
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: APIC-CF, 2ccExperimental Treatment1 Intervention
APIC-CF, 2cc, one at first day
Group II: APIC-CF 4cc,Experimental Treatment1 Intervention
APIC-CF 4cc, once at first day
Group III: SalinePlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Cytonics CorporationLead Sponsor
3 Previous Clinical Trials
322 Total Patients Enrolled
1 Trials studying Osteoarthritis
22 Patients Enrolled for Osteoarthritis
~29 spots leftby Nov 2025